Th e two breast cancer genes BRCA1 and BRCA2 account for approximately one-half of cases of hereditary breast cancer, and other genes, such as BRIP1, PALB2, and P53, account for a small additional fraction [1] . Recently, it has been proposed that RAD51C is also a breast cancer suscep tibility gene [2] . A bi-allelic mutation of RAD51C was originally found in a family from Pakistan with features of Fanconi anemia [3] . Because several genes in the Fanconi anemia gene family are also breast cancer susceptibility genes (including BRCA2 (FANCD1) [4] , BRIP1 (FANCJ) [5] and PALB2 (FANCN) [6]), Meindl and colleagues hypothesised that RAD51C might be a breast cancer gene [2] . A germline mutation was seen in 6 of 480 (1.3%) breast/ovarian cancer families from Germany, which had previously been found to be negative for mutations in BRCA1 and BRCA2. In each of the six families, the putative mutation co-segregated with the relevant cancers [2] . Each family with a mutation contained at least one case each of breast and ovarian cancer.
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In order to confi rm these fi ndings, we sequenced the nine coding exons of RAD51C in the germline DNA of 454 patients with familial breast/ovarian cancer. Th e mean age at diagnosis of the breast cancers was 44.7 years (range 21 to 65) and the mean age of diagnosis of the ovarian cancers was 47.9 years (range 23 to 60 years). All patients were previously found to be negative for BRCA1 and BRCA2 mutations. Each proband had at least two aff ected fi rst-or second-degree relatives. Eighty-fi ve percent of the families contained at least one case of ovarian cancer. One-hundred patients were Jewish, 152 were French-Canadian and 202 were of various other ethnic origins. All subjects provided written informed consent to participate in the study. Th e study protocol was approved by the ethics committee of the Women's College Research Institute, protocol number 2007-0036-B.
We found no deleterious RAD51C mutation among the 454 patients. We found a novel c.146-8A>G splicing variant in three of 100 Jewish breast cancer patients, but this variant was also present in 12 of 190 Jewish controls. In addition, we found one polymorphic missense variant (p.126Ala>Th r or rs61758784) in three patients and one (p.287Th r>Ala or rs28363317) in four patients. Based on the prevalence of mutations in the initial report [2] , we expected to identify approximately fi ve families with a deleterious germline RAD51C mutation. It is of interest that the mutations in the German families were all diff erent, and therefore the discrepant results cannot be explained by the presence of RAD51C founder alleles in Germany. Perhaps RAD51C mutations are not as common as the initial report suggests.
